The polycythemia vera-associated Jak2 V617F mutant induces tumorigenesis in nude mice

被引:23
作者
Abe, Miyuki [1 ]
Funakoshi-Tago, Megumi [1 ]
Tago, Kenji [2 ]
Kamishimoto, Jun [1 ]
Aizu-Yokota, Eriko [1 ]
Sonoda, Yoshiko [1 ]
Kasahara, Tadashi [1 ]
机构
[1] Keio Univ, Fac Pharmacol, Dept Biochem, Minato Ku, Tokyo 1058512, Japan
[2] Nara Inst Sci & Technol, Grad Sch Biol Sci, Dept Cell Biol, Nara 6300101, Japan
关键词
Jak2; Polycythemia vera (PV); V617F; Anti-apoptosis; Tumorigenesis; TYROSINE KINASE; FERM DOMAIN; ERYTHROPOIETIN; RECEPTOR; INHIBITION; LEUKEMIA; MUTATION; CELLS;
D O I
10.1016/j.intimp.2009.03.011
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The somatic Jak2 mutation (V617F) was identified in most patients with polycythemia vera (PV). Here, we show that the activating Jak2 V617F mutant completely protected Ba/F3 cells from cytokine withdrawal-induced apoptotic cell death. Interestingly, Ba/F3 cells expressing Jak2 V617F mutant induced rapid tumorigenesis in nude mice, leading to rapid death. Whereas an injection of Ba/F3 cells expressing wild-type Jak2 had no effect, an injection of Ba/F3 cells expressing Jak2 V617F mutant promptly invaded and spread into various distinct organs, such as the liver and spleen. Strikingly, Jak2 inhibitor, AG490 potently inhibited cytokine-independent cell growth induced by the Jak2 V617F mutant. Also, treatment with AG490 effectively delayed Jak2 V617F mutant-induced tumorigenesis in nude mice. Thus, our results both in vitro and in vivo suggest that Jak2 harboring V617F mutation is a potent oncogene able to promote cell transformation and tumorigenesis. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:870 / 877
页数:8
相关论文
共 26 条
[1]   Protein kinase B (c-Akt), phosphatidylinositol 3-kinase, and STAT5 are activated by erythropoietin (EPO) in HCD57 erythroid cells but are constitutively active in an EPO-independent, apoptosis-resistant subclone (HCD57-SREI cells) [J].
Bao, HF ;
Jacobs-Helber, SM ;
Lawson, AE ;
Penta, K ;
Wickrema, A ;
Sawyer, ST .
BLOOD, 1999, 93 (11) :3757-3773
[2]  
Danilkovitch-Miagkova A, 2002, J CLIN INVEST, V109, P863
[3]   Critical determinants of metastasis [J].
Fidler, IJ .
SEMINARS IN CANCER BIOLOGY, 2002, 12 (02) :89-96
[4]   Licochalcone A is a potent inhibitor of TEL-Jak2-mediated transformation through the specific inhibition of Stat3 activation [J].
Funakoshi-Tago, Megumi ;
Tago, Kenji ;
Nishizawa, Chiho ;
Takahashi, Kyoko ;
Mashino, Tadahiko ;
Iwata, Susumu ;
Inoue, Hideo ;
Sonoda, Yoshiko ;
Kasahara, Tadashi .
BIOCHEMICAL PHARMACOLOGY, 2008, 76 (12) :1681-1693
[5]   Jak2 FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activity [J].
Funakoshi-Tago, Megumi ;
Pelletier, Stephane ;
Moritake, Hiroshi ;
Parganas, Evan ;
Ihle, James N. .
MOLECULAR AND CELLULAR BIOLOGY, 2008, 28 (05) :1792-1801
[6]   Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2 [J].
Funakoshi-Tago, Megumi ;
Pelletier, Stephane ;
Matsuda, Tadashi ;
Parganas, Evan ;
Ihle, James N. .
EMBO JOURNAL, 2006, 25 (20) :4763-4772
[7]   Cotargeting survival signaling pathways in cancer [J].
Grant, Steven .
JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (09) :3003-3006
[8]  
HARPUR AG, 1992, ONCOGENE, V7, P1347
[9]   Jak2: normal function and role in hematopoietic disorders [J].
Ihle, James N. ;
Gilliland, D. Gary .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 2007, 17 (01) :8-14
[10]   A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera [J].
James, C ;
Ugo, V ;
Le Couédic, JP ;
Staerk, J ;
Delhommeau, F ;
Lacout, C ;
Garçon, L ;
Raslova, H ;
Berger, R ;
Bennaceur-Griscelli, A ;
Villeval, JL ;
Constantinescu, SN ;
Casadevall, N ;
Vainchenker, W .
NATURE, 2005, 434 (7037) :1144-1148